Neuro deals aplenty: UCB’s $1B+ takeover of Neurona the latest

A flurry of deals focused on the neurological disease space in 2026 suggest large biopharma companies are searching for the next best therapeutics for everything from epilepsy and narcolepsy to post-traumatic stress disorder and hyperphagia.
2026-04-24 16:00:00